Literature DB >> 31795213

FOXD1 and Gal-3 Form a Positive Regulatory Loop to Regulate Lung Cancer Aggressiveness.

Chien-Hsiu Li1,2, Yu-Chan Chang3, Michael Hsiao3,4, Shu-Mei Liang1,2.   

Abstract

Dysregulation of forkhead box D1 (FOXD1) is known to promote tumor progression; however, its molecular mechanism of action is unclear. Based on microarray analysis, we identified galectin-3/LGALS3 (Gal-3) as a potential downstream target of FOXD1, as FOXD1 transactivated Gal-3 by interacting with the Gal-3 promoter to upregulate Gal-3 in FOXD1-overexpressing CL1-0 lung cancer cells. Ectopic expression of FOXD1 increased the expression of Gal-3 and the growth and motility of lung cancer cells, whereas depletion of Gal-3 attenuated FOXD1-mediated tumorigenesis. ERK1/2 interacted with FOXD1 in the cytosol and translocated FOXD1 into the nucleus to activate Gal-3. Gal-3 in turn upregulated FOXD1 via the transcription factor proto-oncogene 1 (ETS-1) to transactivate FOXD1. The increase in ETS-1/FOXD1 expression by Gal-3 was through Gal-3-mediated integrin-β1 (ITGβ1) signaling. The overexpression of both FOXD1 and Gal-3 form a positive regulatory loop to promote lung cancer aggressiveness. Moreover, both FOXD1 and Gal-3 were positively correlated in human lung cancer tissues. Our findings demonstrated that FOXD1 and Gal-3 form a positive feedback loop in lung cancer, and interference of this loop may serve as an effective therapeutic target for the treatment of lung cancers, particularly those related to dysregulation of Gal-3.

Entities:  

Keywords:  FOXD1; Galectin-3; lung cancer

Year:  2019        PMID: 31795213     DOI: 10.3390/cancers11121897

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  8 in total

1.  LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway.

Authors:  Liping Wu; Yongcun Liu; Cheng Guo; Yuan Shao
Journal:  Cancer Cell Int       Date:  2020-07-09       Impact factor: 5.722

2.  The Expression and Survival Significance of FOXD1 in Lung Squamous Cell Carcinoma: A Meta-Analysis, Immunohistochemistry Validation, and Bioinformatics Analysis.

Authors:  Fang Xie; Yunhui Li; Bin Liang
Journal:  Biomed Res Int       Date:  2022-05-14       Impact factor: 3.246

3.  FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.

Authors:  Huazhen Liang; Chunning Zhang; Chaoming Li; Changguo Li; Yanli Wang; Huaming Lin
Journal:  Biosci Rep       Date:  2021-07-30       Impact factor: 3.840

4.  Galectin‑3 facilitates the proliferation and migration of nasopharyngeal carcinoma cells via activation of the ERK1/2 and Akt signaling pathways, and is positively correlated with the inflammatory state of nasopharyngeal carcinoma.

Authors:  Mei Li; Yu Bin Chen; Fen Liu; Jia Quan Qu; Li Cheng Ren; Jin Chai; Can E Tang
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

5.  Aberrant overexpression of transcription factor Forkhead box D1 predicts poor prognosis and promotes cancer progression in HNSCC.

Authors:  Jin Li; Tingyuan Yan; Xiang Wu; Xueping Ke; Xin Li; Yumin Zhu; Jianrong Yang; Zhongwu Li
Journal:  BMC Cancer       Date:  2021-11-12       Impact factor: 4.430

6.  E2F transcription factor 1/small nucleolar RNA host gene 18/microRNA-338-5p/forkhead box D1: an important regulatory axis in glioma progression.

Authors:  Quanfeng Ma; Tianhao Yang
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

7.  FOXD1 facilitates pancreatic cancer cell proliferation, invasion, and metastasis by regulating GLUT1-mediated aerobic glycolysis.

Authors:  Kun Cai; Shiyu Chen; Changhao Zhu; Lin Li; Chao Yu; Zhiwei He; Chengyi Sun
Journal:  Cell Death Dis       Date:  2022-09-03       Impact factor: 9.685

8.  The MUC5B-associated variant rs35705950 resides within an enhancer subject to lineage- and disease-dependent epigenetic remodeling.

Authors:  Fabienne Gally; Sarah K Sasse; Jonathan S Kurche; Margaret A Gruca; Jonathan H Cardwell; Tsukasa Okamoto; Hong W Chu; Xiaomeng Hou; Olivier B Poirion; Justin Buchanan; Sebastian Preissl; Bing Ren; Sean P Colgan; Robin D Dowell; Ivana V Yang; David A Schwartz; Anthony N Gerber
Journal:  JCI Insight       Date:  2021-01-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.